Opdivo

Encouraging signs in biomarker R&D

In June 2018, Bristol Myers-Squibb sought approval for Opdivo and low-dose Yervoy in lung cancer in patients with a TMB of greater than ten mutations per megabase. ... impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.

Third strike for BMS’ Opdivo in brain cancer

Despite failing first endpoint, trial is set to continue. Bristol-Myers Squibb’s (BMS) immuno-oncology blockbuster Opdivo has failed a third straight clinical trial in the hard-to-treat brain ... Opdivo plus standard first-line temozolomide and

Roche scores EU approval twice for Tecentriq in lung cancer

Bristol-Myers Squibb is also testing its own PD-1 inhibitor Opdivo (nivolumab) in this indication, with a trial currently in phase 2.

MSD’s Keytruda catches up in kidney cancer

This is an improvement on BMS’ rival therapy Opdivo, which won its approval on the back of the phase 3 CheckMate-214 clinical trial in January.This trial showed that Opdivo ... It also has another advantage over Opdivo, having been approved

Celgene boosts IO presence with Immatics deal

These candidates are among the most promising in Celgene’s portfolio, and once the merger is complete, with create a formidable oncology franchise, adding to BMS' checkpoint inhibitor blockbuster Opdivo. ... BMS/Celgene know they must build their

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]